| Literature DB >> 24041479 |
Linda Bolier1, Merel Haverman, Jeannet Kramer, Gerben J Westerhof, Heleen Riper, Jan A Walburg, Brigitte Boon, Ernst Bohlmeijer.
Abstract
BACKGROUND: Depression is a worldwide problem warranting global solutions to tackle it. Enhancing well-being has benefits in its own right and could be a good strategy for preventing depression. Providing well-being interventions via the Internet may have synergetic effects.Entities:
Keywords: Internet; depression; prevention; public health; randomized controlled trial; well-being
Mesh:
Year: 2013 PMID: 24041479 PMCID: PMC3929047 DOI: 10.2196/jmir.2603
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Screenshot of the Psyfit website.
Figure 2Participants’ flow through the study.
Baseline characteristics of participants.
| Characteristic | Psyfit (n=143) | Control group (n=141) | All (N=284) | |
| Age (years), mean, (SD) | 43.5 (11.7) | 42.8 (11.9) | 43.2 (11.8) | |
|
|
|
|
| |
|
| 21-34 years | 36 (25.2) | 37 (26.2) | 73 (25.7) |
|
| 35-64 years | 100 (69.9) | 101 (71.6) | 201 (70.8) |
|
| 65-100 years | 7 (4.9) | 3 (2.1) | 10 (3.5) |
| Female, n (%) | 114 (79.7) | 112 (79.4) | 226 (79.6) | |
| Major negative life event (yes), n (%) | 80 (55.9) | 73 (51.8) | 153 (53.9) | |
|
|
|
|
| |
|
| Lower (up to high school and middle-level applied education) | 39 (27.3) | 37 (26.2) | 76 (26.8) |
|
| Higher (academic/professional) | 104 (72.7) | 104 (73.8) | 208 (73.2) |
|
|
|
|
| |
|
| Paid employment | 106 (74.1) | 108 (76.6) | 214 (75.4) |
|
| Unemployed/unable to work | 20 (14.0) | 10 (7.1) | 30 (10.6) |
|
| Other (student, at home, retired) | 17 (11.9) | 23 (16.3) | 40 (14.1) |
|
|
|
|
| |
|
| With partner, with or without children | 92 (64.3) | 84 (59.6) | 176 (62.0) |
|
| No partner, with or without children | 45 (31.5) | 48 (34.0) | 93 (32.7) |
|
| Other (dorm or with parents) | 6 (4.2) | 9 (6.4) | 15 (5.3) |
|
|
|
|
| |
|
| MHC-SF (well-being) | 3.45 (0.62) | 3.50 (0.63) | 3.47 (0.63) |
|
| WHO-5 (well-being) | 10.81 (4.31) | 11.52 (4.38) | 11.17 (4.35) |
|
| CES-D (depression) | 16.91 (4.16) | 16.67 (4.11) | 16.80 (4.13) |
|
| HADS-A (anxiety) | 6.55 (2.86) | 6.53 (2.96) | 6.54 (2.91) |
|
| MOS SF subscale general health | 18.57 (3.51) | 17.95 (3.61) | 18.26 (3.57) |
|
| MOS SF subscale vitality | 14.46 (3.16) | 14.62 (2.83) | 14.54 (3.00) |
Effects of Psyfit, intention-to-treat analysis.
| Measures | Psyfit (n=143) | Control group (n=141) | Linear regression analysis | ||||||||
|
| Mean | SD |
| Mean | SD |
| Beta |
|
| ∆ | |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 3.45 | 0.62 |
| 3.50 | 0.63 |
|
|
|
|
|
|
| 2-month | 3.92 | 0.71 | 0.71 | 3.82 | 0.82 | 0.44 | 0.09 | 1.88 | .06 | 0.27 |
|
| 6-month | 3.88 | 0.79 | 0.61 | 3.90 | 0.71 | 0.60 | 0.01 | 0.13 | .90 | 0.01 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 10.81 | 4.31 |
| 11.52 | 4.38 |
|
|
|
|
|
|
| 2-month | 12.75 | 4.47 | 0.44 | 12.12 | 4.63 | 0.13 | 0.12 | 2.47 | .01 | 0.31 |
|
| 6-month | 12.92 | 4.77 | 0.47 | 12.45 | 4.61 | 0.21 | 0.09 | 1.61 | .11 | 0.26 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 16.91 | 4.16 |
| 16.67 | 4.12 |
|
|
|
|
|
|
| 2-month | 13.67 | 6.69 | 0.57 | 15.39 | 7.64 | 0.21 | –0.13 | –2.33 | .02 | 0.36 |
|
| 6-month | 13.06 | 7.55 | 0.63 | 14.94 | 7.48 | 0.28 | –0.13 | –2.38 | .02 | 0.35 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 6.55 | 2.86 |
| 6.53 | 2.96 |
|
|
|
|
|
|
| 2-month | 5.75 | 2.90 | 0.28 | 6.64 | 3.08 | –0.04 | –0.15 | –3.29 | .001 | 0.32 |
|
| 6-month | 5.65 | 3.39 | 0.29 | 6.70 | 2.98 | –0.06 | –0.17 | –3.38 | .001 | 0.35 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 18.57 | 3.51 |
| 17.95 | 3.61 |
|
|
|
|
|
|
| 2-month | 19.21 | 3.16 | 0.19 | 18.11 | 3.50 | 0.05 | 0.09 | 2.72 | .01 | 0.14 |
|
| 6-month | 18.65 | 3.41 | 0.02 | 18.20 | 3.51 | 0.07 | 0.00 | –0.68 | .95 | –0.05 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 14.46 | 3.16 |
| 14.62 | 2.83 |
|
|
|
|
|
|
| 2-month | 15.74 | 3.09 | 0.41 | 15.14 | 2.76 | 0.19 | 0.12 | 2.33 | .02 | 0.22 |
|
| 6-month | 15.70 | 3.57 | 0.37 | 15.20 | 3.01 | 0.20 | 0.09 | 1.70 | .09 | 0.17 |
Figure 3Depicted scores at baseline, 2-, and 6-month follow-ups for the MHC-SF, WHO-5, and CES-D (intention-to-treat sample).
Effects of Psyfit, completers-only analysis.
| Measures | Psyfita | Control groupb | Linear regression analysis | ||||||||
|
| Mean | SD |
| Mean | SD |
| Beta |
|
| ∆ | |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 3.52 | 0.63 |
| 3.51 | 0.63 |
|
|
|
|
|
|
| 2-month | 3.95 | 0.81 | 0.59 | 3.81 | 0.85 | 0.40 | 0.08 | 1.50 (211) | .14 | 0.19 |
|
| Baseline | 3.51 | 0.61 |
| 3.50 | 0.64 |
|
|
|
|
|
|
| 6-month | 3.89 | 0.84 | 0.52 | 3.91 | 0.76 | 0.58 | –0.20 | –0.32 (195) | .75 | –0.06 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 11.27 | 4.45 |
| 11.45 | 4.32 |
|
|
|
|
|
|
| 2-month | 12.98 | 5.11 | 0.36 | 11.97 | 4.78 | 0.11 | 0.11 | 1.98 (211) | .049 | 0.25 |
|
| Baseline | 11.07 | 4.37 |
| 11.58 | 4.45 |
|
|
|
|
|
|
| 6-month | 12.72 | 5.44 | 0.33 | 12.59 | 4.84 | 0.22 | 0.04 | 0.57 (195) | .57 | 0.11 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 16.57 | 4.12 |
| 16.55 | 4.18 |
|
|
|
|
|
|
| 2-month | 13.35 | 7.97 | 0.51 | 15.58 | 8.11 | 0.16 | –0.14 | –2.12 (211) | .04 | 0.35 |
|
| Baseline | 17.04 | 4.14 |
| 16.66 | 4.00 |
|
|
|
|
|
|
| 6-month | 13.35 | 8.64 | 0.54 | 14.87 | 8.04 | 0.28 | –0.10 | –1.50 (195) | .14 | 0.26 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 6.27 | 2.83 |
| 6.52 | 3.03 |
|
|
|
|
|
|
| 2-month | 5.49 | 3.18 | 0.26 | 6.68 | 3.24 | –0.05 | –0.16 | –2.89 (211) | .004 | 0.31 |
|
| Baseline | 6.28 | 2.78 |
| 6.57 | 2.95 |
|
|
|
|
|
|
| 6-month | 5.55 | 3.78 | 0.22 | 6.69 | 3.23 | –0.04 | –0.14 | –2.24 (195) | .03 | 0.26 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 18.66 | 3.50 |
| 17.97 | 3.66 |
|
|
|
|
|
|
| 2-month | 19.40 | 3.31 | 0.22 | 18.09 | 3.61 | 0.03 | 0.11 | 2.59 (211) | .01 | 0.19 |
|
| Baseline | 18.39 | 3.40 |
| 18.39 | 3.35 |
|
|
|
|
|
|
| 6-month | 18.57 | 3.58 | 0.05 | 18.61 | 3.36 | 0.07 | –0.01 | –0.11 (195) | .91 | –0.02 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 14.67 | 3.17 |
| 14.66 | 2.82 |
|
|
|
|
|
|
| 2-month | 15.80 | 3.39 | 0.34 | 15.09 | 2.86 | 0.15 | 0.11 | 1.88 (211) | .06 | 0.19 |
|
| Baseline | 14.37 | 3.29 |
| 14.80 | 2.83 |
|
|
|
|
|
|
| 6-month | 15.53 | 3.99 | 0.32 | 15.39 | 3.15 | 0.20 | 0.048 | 0.74 (195) | .46 | 0.12 |
a2-month follow-up: n=95, 6-month follow-up: n=89.
b2-month follow-up: n=119, 6-month follow-up: n=109.
Adherence grades and effect sizes, intention-to-treat sample (experimental group, Cohen’s d pre-post).
| Measures | <1 lesson (n=31) | 1 lesson (n=46) | 2 lessons (n=24) | 3 lessons (n=29) | ≥4 lessons (n=13) | ||||||
|
| Mean (SD) |
| Mean (SD) |
| Mean (SD) |
| Mean (SD) |
| Mean (SD) |
| |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 3.46 (0.60) |
| 3.46 (0.70) |
| 3.17 (0.58) |
| 3.52 (0.52) |
| 3.69 (0.62) |
|
|
| 2-month | 3.84 (0.61) | 0.63 | 3.90 (0.64) | 0.66 | 4.05 (0.81) | 1.25 | 3.92 (0.68) | 0.66 | 3.99 (1.04) | 0.36 |
|
| 6-month | 3.74 (0.69) | 0.43 | 3.87 (0.79) | 0.55 | 3.98 (0.78) | 1.18 | 3.94 (0.76) | 0.65 | 3.91 (1.09) | 0.25 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 10.00 (3.59) |
| 11.74 (4.22) |
| 9.75 (5.33) |
| 10.41 (4.45) |
| 12.31 (3.22) |
|
|
| 2-month | 12.00 (3.21) | 0.59 | 12.83 (4.01) | 0.26 | 13.34 (6.24) | 0.62 | 12.09 (4.01) | 0.40 | 14.69 (5.60) | 0.52 |
|
| 6-month | 11.56 (3.91) | 0.42 | 13.28 (4.76) | 0.34 | 13.29 (5.48) | 0.65 | 12.80 (4.93) | 0.51 | 14.55 (4.86) | 0.54 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 17.71 (4.19) |
| 16.28 (3.71) |
| 17.58 (4.74) |
| 17.41 (4.33) |
| 14.92 (3.73) |
|
|
| 2-month | 15.21 (6.21) | 0.47 | 13.73 (5.77) | 0.53 | 13.99 (9.74) | 0.47 | 13.61 (6.77) | 0.67 | 9.31 (5.92) | 1.13 |
|
| 6-month | 14.06 (6.51) | 0.67 | 14.42 (7.67) | 0.31 | 12.16 (8.56) | 0.78 | 12.03 (7.94) | 0.84 | 9.85 (5.90) | 1.03 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 6.90 (2.53) |
| 6.52 (2.96) |
| 7.04 (3.21) |
| 6.00 (3.11) |
| 6.15 (2.03) |
|
|
| 2-month | 6.28 (2.47) | 0.25 | 6.22 (2.88) | 0.10 | 5.58 (3.62) | 0.35 | 4.71 (2.58) | 0.45 | 5.00 (2.80) | 0.47 |
|
| 6-month | 6.16 (3.19) | 0.26 | 6.01 (3.37) | 0.16 | 6.08 (4.00) | 0.26 | 4.62 (2.94) | 0.46 | 4.61 (3.40) | 0.55 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 18.52 (2.74) |
| 18.46 (3.82) |
| 19.00 (3.95) |
| 19.14 (3.55) |
| 17.00 (3.06) |
|
|
| 2-month | 18.98 (2.74) | 0.17 | 19.05 (3.14) | 0.17 | 19.47 (4.05) | 0.12 | 19.48 (2.80) | 0.11 | 19.31 (3.43) | 0.71 |
|
| 6-month | 17.82 (2.81) | –0.25 | 19.07 (3.29) | 0.17 | 18.88 (4.41) | –0.03 | 19.06 (3.30) | 0.02 | 17.85 (3.34) | 0.27 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Baseline | 14.03 (2.77) |
| 15.04 (3.17) |
| 13.96 (3.97) |
| 14.00 (2.87) |
| 15.38 (2.84) |
|
|
| 2-month | 15.20 (2.16) | 0.48 | 15.83 (3.29) | 0.24 | 16.83 (3.81) | 0.74 | 15.21 (2.82) | 0.43 | 15.85 (3.24) | 0.16 |
|
| 6-month | 15.03 (2.77) | 0.36 | 15.90 (3.64) | 0.25 | 15.85 (4.23) | 0.46 | 16.01 (3.67) | 0.61 | 15.62 (3.91) | 0.07 |
Repeated measures analysis on adherence grades (see Table 4).
| Measures | Time | Time×group | ||
|
|
|
|
|
|
| MHC-SF | 34.20 | <.001 | 1.72 | .09 |
| WHO-5 | 18.06 | <.001 | 0.95 | .48 |
| CES-D | 30.00 | <.001 | 0.99 | .44 |
| HADS-A | 9.20 | <.001 | 0.53 | .83 |
| MOS SF health | 14.29 | <.001 | 2.16 | .03 |
| MOS SF vitality | 13.53 | <.001 | 1.75 | .09 |